325 related articles for article (PubMed ID: 17272944)
1. Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.
Gursoy A; Erdogan MF; Cin MO; Cesur M; Baskal N
Eat Weight Disord; 2006 Dec; 11(4):e127-32. PubMed ID: 17272944
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
4. The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.
Douglas IJ; Bhaskaran K; Batterham RL; Smeeth L
Br J Clin Pharmacol; 2015 Jun; 79(6):1020-7. PubMed ID: 25641659
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
[TBL] [Abstract][Full Text] [Related]
6. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
7. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
8. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
9. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
[TBL] [Abstract][Full Text] [Related]
10. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
[TBL] [Abstract][Full Text] [Related]
11. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
Elfhag K; Finer N; Rössner S
Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
[TBL] [Abstract][Full Text] [Related]
12. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
[TBL] [Abstract][Full Text] [Related]
14. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?
Aydin N; Topsever P; Kaya A; Karasakal M; Duman C; Dağar A
Tohoku J Exp Med; 2004 Mar; 202(3):173-80. PubMed ID: 15065643
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
García Díaz E; Martín Folgueras T
Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
[TBL] [Abstract][Full Text] [Related]
16. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
Kiortsis DN; Tsouli S; Filippatos TD; Konitsiotis S; Elisaf MS
Nutr Metab Cardiovasc Dis; 2008 Mar; 18(3):207-10. PubMed ID: 17570651
[TBL] [Abstract][Full Text] [Related]
17. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Leung WY; Thomas GN; Chan JC; Tomlinson B
Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
Chou KM; Huang BY; Fanchiang JK; Chen CH
Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
[TBL] [Abstract][Full Text] [Related]
19. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
[TBL] [Abstract][Full Text] [Related]
20. [Anti-obesity drugs: sibutramine and orlistat].
Sempere I Verdú E; Palop Larrea V; Hidalgo Mora JJ; Martínez-Mir I
Med Clin (Barc); 2002 Mar; 118(11):437; author reply 437-8. PubMed ID: 11943108
[No Abstract] [Full Text] [Related]
[Next] [New Search]